| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/01/2003 | CA2461545A1 Drugs comprising combination of triazaspiro¬5,5|undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or p-glycoprotein inhibitor |
| 05/01/2003 | CA2461182A1 Use of tyrosine kinase inhibitors for promoting hair growth |
| 05/01/2003 | CA2461181A1 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
| 05/01/2003 | CA2461085A1 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol |
| 05/01/2003 | CA2458542A1 Enzyme inhibitors for inactivating allergens |
| 04/30/2003 | CN1415074A Method of detection of amyloidogenic proteins |
| 04/30/2003 | CN1414954A Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, method of production and pharmaceutical uses thereof |
| 04/30/2003 | CN1414871A Placental human necerokinin B precursor |
| 04/30/2003 | CN1414865A 癌症的治疗 Treatment of cancer |
| 04/30/2003 | CN1414864A Adhesive particle DNA constructs and method of making and using the same |
| 04/30/2003 | CN1414863A Treatment of DNA viral infections |
| 04/30/2003 | CN1414862A Antidiabetic formulation and method |
| 04/30/2003 | CN1414859A Combinations for treatment of DNA viral infections |
| 04/30/2003 | CN1414858A Combinations of receptor tyrosine kinase inhibitor with a1-acidic glycoprotein binding organic compound |
| 04/30/2003 | CN1414857A Treatment of drug-resistant human immunodeficiency virus infection |
| 04/30/2003 | CN1414851A Method and formulation for treating resistance to antihypertensives and related conditions |
| 04/30/2003 | CN1414848A Prevention of plaque rupure by ACAT inhibitors |
| 04/30/2003 | CN1414834A Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 04/30/2003 | CN1413734A Biological product for curing ulcerative colitis and preparation method |
| 04/30/2003 | CN1413731A Macrophage tumor vaccin and its preparation method |
| 04/30/2003 | CN1107072C Programing cell death induced molecule II |
| 04/30/2003 | CN1106842C Usage of glutathione accelerator in preparating medicine for treating macular degeneration |
| 04/30/2003 | CN1106841C Compositions for treatment of skin disorders |
| 04/29/2003 | USRE38103 Preferential, nontoxic oxidoreductase inhibitors such as 5-Methanesulfonamido-6-(2,4-difluorophenylthio)-1-indanone administered for prophylaxis of gastrointestinal disorders |
| 04/29/2003 | US6555710 Aminobenzophenones as inhibitors of IL-1 β and TNF-α |
| 04/29/2003 | US6555675 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance |
| 04/29/2003 | US6555667 Hypoxia-regulated genes |
| 04/29/2003 | US6555583 Therapies for treating pulmonary diseases |
| 04/29/2003 | US6555582 Eye treatments using synthetic thyroid hormone compositions |
| 04/29/2003 | US6555578 Thyromimetic antiobesity agents |
| 04/29/2003 | US6555577 Compounds, their preparation and use |
| 04/29/2003 | US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 04/29/2003 | US6555573 Comprising a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor, antioxidant and carrier; side effect reduction; partial recovery of neurological function in some cases |
| 04/29/2003 | US6555569 Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| 04/29/2003 | US6555566 Methods and materials for treating and preventing inflammation of mucosal tissue |
| 04/29/2003 | US6555548 Administering therapeutically effective amount of active agent selected from the group consisting of a heterocyclic amine-type compound, a substituted phenylazacycloalkane-type compound, and a cabergoline-type compound, and their salts |
| 04/29/2003 | US6555546 Use of 5HT3 antagonists for promoting intestinal lavage |
| 04/29/2003 | US6555545 Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents |
| 04/29/2003 | US6555542 Sulfonamide lactam inhibitors of FXa and method |
| 04/29/2003 | US6555540 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 04/29/2003 | US6555532 Using estrogen receptor antagonists such as tamoxifen |
| 04/29/2003 | US6555526 Trehalos; Sjogren syndrome. |
| 04/29/2003 | US6555519 O-glucosylated benzamide SGLT2 inhibitors and method |
| 04/29/2003 | US6555352 Peptide for use in human therapeutics and diagnostic compositions |
| 04/29/2003 | US6555341 Gamma-aminobutyric acid (GABA); stably co-transfected eukaryotic cell line capable of expressing a human GABAa receptor which comprises a theta receptor subunit and at least one receptor subunit; drug screening |
| 04/29/2003 | US6555339 Altering human G protein-coupled receptors (GPCRs) by point mutation; use in drug screening |
| 04/29/2003 | US6555338 Given nucleotide sequence; use of polynucleotides and polypeptides in diagnostic assays, and possibly functional genomics |
| 04/29/2003 | US6555137 Sucralfate-containing composition and process for the preparation thereof |
| 04/29/2003 | US6555136 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 04/29/2003 | US6555124 Reversibly increasing the permeability to active agents of epithelial cells; applied orally, sublingually, buccally, rectally, pulmonarily or nasally or through the mucosa of the eye. |
| 04/26/2003 | CA2409084A1 Anti-inflammatory agent and foods and drinks containing the same |
| 04/26/2003 | CA2395909A1 Anti-inflammatory agent and foods and drinks containing the same |
| 04/24/2003 | WO2003034791A1 Mounting arrangement for auxiliary burner or lance |
| 04/24/2003 | WO2003034067A1 Modulation of tor |
| 04/24/2003 | WO2003034063A1 Method of screening remedy for atrial fibrillation |
| 04/24/2003 | WO2003034028A2 Methods for identifying and using modulators of estrogen related receptor gamma |
| 04/24/2003 | WO2003033681A2 Composition comprising a lactobacillus pentosus strain and uses thereof |
| 04/24/2003 | WO2003033680A2 Kinases and phosphatases |
| 04/24/2003 | WO2003033671A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 04/24/2003 | WO2003033664A2 Bone anti-resorptive compounds |
| 04/24/2003 | WO2003033660A2 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 04/24/2003 | WO2003033654A2 Direct targeting binding proteins |
| 04/24/2003 | WO2003033653A2 Affinity enhancement agents |
| 04/24/2003 | WO2003033518A1 Steroidal compounds for inhibiting steroid sulphatase |
| 04/24/2003 | WO2003033513A1 Differentially expressed genes associated with obesity and type 2 diabetes |
| 04/24/2003 | WO2003033496A1 Beta-carbolin derivatives as ptp-inhibitors |
| 04/24/2003 | WO2003033487A1 Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 04/24/2003 | WO2003033031A1 Dosage form, device and methods of treatment |
| 04/24/2003 | WO2003033025A2 Cyclodextrin complexes |
| 04/24/2003 | WO2003033015A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 04/24/2003 | WO2003033003A1 Agent controlling the production of osteoclast formation regulator and method of screening substance capable of controlling the production of osteoclast formation regulator |
| 04/24/2003 | WO2003033001A1 Combinations comprising cox-2 inhibitors and aspirin |
| 04/24/2003 | WO2003033000A1 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
| 04/24/2003 | WO2003032996A1 Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists |
| 04/24/2003 | WO2003032990A2 Polymer conjugates of opioid antagonists |
| 04/24/2003 | WO2003032985A2 Concomitant oral and topical administration of anti - infective agents |
| 04/24/2003 | WO2003032984A1 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer |
| 04/24/2003 | WO2003032982A1 Bis-heteroaryl alkanes as therapeutic agents |
| 04/24/2003 | WO2003032975A1 Modulation of ocular growth and myopia by gaba drugs |
| 04/24/2003 | WO2003032965A2 Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
| 04/24/2003 | WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | WO2003032963A2 Method of reducing type 2 diabetes in high risk patients |
| 04/24/2003 | WO2003032961A2 Methods for preventing and treating bone loss with steroid compounds |
| 04/24/2003 | WO2003032955A1 Highly compressible ethylcellulose for tableting |
| 04/24/2003 | WO2003032948A2 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity |
| 04/24/2003 | WO2003032944A1 Anti-microbial composition comprising a metal ion chelating agent |
| 04/24/2003 | WO2003032941A2 Cosmetic and/or dermatological active ingredient combination |
| 04/24/2003 | WO2003032928A2 Therapeutic composition and use |
| 04/24/2003 | WO2003032926A2 Compositions and methods for reversal of drug resistance |
| 04/24/2003 | WO2003032912A2 Treatment of cns disorders using cns target modulators |
| 04/24/2003 | WO2003032909A2 Methods of treating skin with diphosphonate derivatives |
| 04/24/2003 | WO2003032904A2 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| 04/24/2003 | WO2003032897A2 Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| 04/24/2003 | WO2003032895A2 Methods and pharmaceutical compositions for stimulating the immune system and/or treating cancer |
| 04/24/2003 | WO2003032894A2 Method of monitoring neuroprotective treatment |
| 04/24/2003 | WO2003032866A2 Detection and treatment of intravascular lesions |
| 04/24/2003 | WO2003032814A2 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
| 04/24/2003 | WO2003032813A2 Methods for the treatment of carcinoma |
| 04/24/2003 | WO2003032810A2 Treatment and diagnosis of insulin resistant states |
| 04/24/2003 | WO2003032735A1 Remodeling of tissues and organs |